NCT00001439View on ClinicalTrials.gov

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

PHASE1CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

June 30, 1995

Study Completion Date

April 30, 2000

Conditions
Melanoma
Interventions
BIOLOGICAL

gp100 human melanoma peptide

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001439 - A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant | Biotech Hunter | Biotech Hunter